Search Results

Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes.

• Authors : Fritsche, Andreas; Schweitzer, Matthias Axel; Häring, Hans-Ulrich

Subjects: TYPE 2 diabetes treatment; INSULIN; HYPOGLYCEMIA

• Source: Annals of Internal Medicine. 6/17/2003, Vol. 138 Issue 12, p952. 9p.

Record details

Addition of Neutral Protamine Lispro Insulin or Insulin Glargine to Oral Type 2 Diabetes Regimens for Patients with Suboptimal Glycemic Control.

• Authors : Esposito, Katherine; Ciotola, Miryam; Maiorino, Maria Ida

Subjects: TYPE 2 diabetes; HYPOGLYCEMIC agents; BLOOD sugar

• Source: Annals of Internal Medicine. 10/21/2008, Vol. 149 Issue 8, p531-539. 10p. 1 Diagram, 2 Charts, 3 Graphs.

Record details

Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes.

• Authors : Heine, Robert J.; Van Gaal, Luc F.; Johns, Don

Subjects: INSULIN; TYPE 2 diabetes; BLOOD sugar

• Source: Annals of Internal Medicine. 10/18/2005, Vol. 143 Issue 8, p559-W130. 12p.

Record details

Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5): A Randomized Trial.

• Authors : Bajaj, Harpreet S.; Aberle, Jens; Davies, Melanie

Subjects: TYPE 2 diabetes; INSULIN therapy; INSULINNOVO Nordisk A/S

• Source: Annals of Internal Medicine; Nov2023, Vol. 176 Issue 11, p1476-1485, 11p

Record details

Exenatide or Insulin Glargine for Suboptimally Controlled Diabetes?

• Authors : Heine, R. J.; Van Gaal, L. F.; Johns, D.

Subjects: TYPE 2 diabetes; BLOOD sugar; DRUGS

• Source: Annals of Internal Medicine. 10/18/2005, Vol. 143 Issue 8, pI30-I30. 1p.

Record details

Correction: Summaries for Patients: Exenatide or Insulin Glargine for Suboptimally Controlled Type 2 Diabetes?

Subjects: TYPE 2 diabetes

• Source: Annals of Internal Medicine; 4/18/2006, Vol. 144 Issue 8, p620-620, 1/8p

Record details

Summaries for patients. Exenatide or insulin glargine for suboptimally controlled diabetes?

• Authors : Heine RJ; Van Gaal LF; Johns D

• Source: Annals of Internal Medicine; 10/18/2005, Vol. 143 Issue 8, pI30-I30, 1p

Record details

First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.

• Authors : Hanna, Caroline¹ (AUTHOR); Pettersen, Kenneth¹ (AUTHOR); Pedley, Nathaniel¹ (AUTHOR)

Subjects: *GLUCAGON-like peptide-1 agonists; *GLUCAGON-like peptide-1 receptor; *TYPE 2 diabetes

• Source: Annals of Internal Medicine. Apr2023, Vol. 176 Issue 4, p1-2. 2p.

Record details

Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.

• Authors : Bersoff-Matcha, Susan J.; Chamberlain, Christine; Cao, Christian

Subjects: SEPTIC shock; DIABETIC acidosis; NECROTIZING fasciitisUNITED States. Food & Drug Administration

• Source: Annals of Internal Medicine; 6/4/2019, Vol. 170 Issue 11, p764-769, 6p, 1 Chart

Record details

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

• Authors : Buse JB; Bergenstal RM; Glass LC

• Source: Annals of Internal Medicine; 1/18/2011, Vol. 154 Issue 2, p103-112, 10p

Record details